Running a clinical trial is one of the most expensive, time-consuming, and failure-prone processes in all of medicine. Israeli startup QuantiHealth thinks it has a shortcut — and investors just backed that bet with $45 million. The company, which builds AI-powered simulation technology designed to model how drugs behave in human populations before a single patient is enrolled, announced the Series B round as demand for faster, cheaper drug development pathways reaches a fever pitch across the pharmaceutical industry. If you’ve been following the broader wave of AI clinical trials investment, QuantiHealth is one of the most aggressive players in that space.
According to Globes, the Tel Aviv-based company uses its platform to simulate clinical trial outcomes computationally, allowing drug developers to optimize trial design, predict patient responses, and identify failure points before committing the massive resources a real-world trial demands. The implications are enormous: Phase III trials alone can cost upward of $300 million and take years to complete, and the majority still fail.
What the Platform Actually Does
QuantiHealth’s core technology ingests vast datasets — electronic health records, biomarker profiles, genomic data, and prior trial results — to build synthetic patient populations that mirror real-world diversity. The AI then runs thousands of simulated trial scenarios to surface which protocols are most likely to succeed, which patient cohorts to target, and where statistical power is being left on the table. The result is a kind of computational pre-flight check for drug developers that could dramatically shrink the guesswork baked into conventional trial design.
This matters beyond just cost savings. One of the persistent problems in drug development is that trials are often designed around patient populations that don’t reflect the people who will eventually take the medication. AI-driven simulation can help sponsors stress-test their protocols against broader demographic profiles before regulatory submission — a capability that regulators in the US and Europe are increasingly open to as part of modernized drug approval frameworks.
The Funding and What Comes Next
The $45 million raise gives QuantiHealth the runway to expand its commercial partnerships with pharmaceutical companies and grow its engineering and data science teams. The company is operating in a competitive but still wide-open market — pharma’s digital transformation has been slower than nearly every other major industry, meaning the ceiling for adoption is high. Israeli deep-tech has been punching above its weight in this space, with several AI-in-medicine startups drawing significant international capital. Israeli AI investment broadly has continued to attract global venture attention even amid a tighter funding environment.
The Series B positions QuantiHealth to move from early commercial traction into scaled deployment across multiple drug development programs simultaneously. Globes reported the raise but did not disclose the specific lead investor or the full cap table. What is clear is that the company is no longer a proof-of-concept play — at $45 million in fresh capital, it is building infrastructure intended to sit at the center of how the next generation of drugs gets designed, tested, and brought to market. The question is whether the pharmaceutical establishment, notoriously cautious about disruption, will move fast enough to meet it.
